ArticleHealth science reports2026
miR-1246 as a Diagnostic, Prognostic, and Therapeutic Biomarker in Breast Cancer: A Narrative Review With Pharmacoeconomic Perspectives.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: MicroRNA-1246 (miR-1246) has emerged as an important regulatory molecule in breast cancer, with growing evidence supporting its role in diagnosis, prognosis, and therapeutic response. This review aims to evaluate the diagnostic, prognostic, and therapeutic significance of miR-1246 in breast cancer and to assess its potential pharmacoeconomic impact on clinical practice. Methods: A narrative review was conducted using a structured literature search of PubMed, Scopus, and Web of Science databases. Study identification and selection were informed by PRISMA screening principles to enhance transparency and reproducibility; however, this review was not conducted as a formal systematic review or meta-analysis. Studies investigating miR-1246 expression patterns, associations with clinicopathological features, patient outcomes, therapeutic responses, and pharmacoeconomic aspects, including cost-effectiveness of diagnostic and therapeutic applications, were included. Results: Elevated miR-1246 expression was consistently associated with aggressive breast cancer phenotypes, particularly triple-negative breast cancer (TNBC), and poorer clinical outcomes. Several studies demonstrated that targeting miR-1246 enhances the efficacy of hormone therapy and immunotherapy, suggesting a role in overcoming treatment resistance. Pharmacoeconomic evaluations indicated that integrating miR-1246 into diagnostic and therapeutic strategies may have the potential to be cost-effective, provided that future economic evaluations confirm improvements in early detection and treatment selection. Conclusion: miR-1246 shows strong potential as a diagnostic and prognostic biomarker and as a therapeutic target in breast cancer. Despite promising findings, further clinical validation and standardized integration into routine practice are required to fully establish its clinical and economic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.